Autoantibodies against galactose-deficient IgA1 drive formation of pathogenic immune complexes in IgA nephropathy. IgG autoantibodies against galactose-deficient IgA1 in patients with IgA nephropathy have a specific amino-acid sequence, Y1CS3, in the complementarity-determining region 3 of the heavy chain variable region compared with a Y1CA3 sequence in similar isotype-matched IgG from healthy controls. We previously found that the S3 residue is critical for binding galactose-deficient IgA1. To determine whether this difference is due to a rare germline sequence, we amplified and sequenced the corresponding germline variable region genes from peripheral blood mononuclear cells of seven patients with IgA nephropathy and six healthy controls from whom we had cloned single-cell lines secreting monoclonal IgG specific for galactose-deficient IgA1. Sanger DNA sequencing revealed that complementarity-determining region 3 in the variable region of the germline genes encoded the Y1C(A/V)3 amino-acid sequence. Thus, the A/V>S substitution in the complementarity-determining region 3 of anti-galactose-deficient-IgA1 autoantibodies of the patients with IgA nephropathy is not a rare germline gene variant. Modeling analyses indicated that the S3 hydroxyl group spans the complementarity-determining region 3 loop stem, stabilizing the adjacent β-sheet and stem structure, important features for effective binding to galactose-deficient IgA1. Understanding processes leading to production of the autoantibodies may offer new approaches to treat IgA nephropathy.

Columbia University New York New York

Juntendo University Faculty of Medicine Tokyo Japan

Palacky University and University Hospital Olomouc Olomouc Czech Republic

University of Alabama at Birmingham Birmingham Alabama

University of Alabama at Birmingham Birmingham Alabama;

University of Nebraska Medical Center Omaha Nebraska

University of Tennessee Health Science Center Memphis Tennessee; and

West China 2nd University Hospital State Key Laboratory of Biotherapy Sichuan University Chengdu China

Zobrazit více v PubMed

Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA: The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22: 1795–1803, 2011 PubMed PMC

Glassock RJ: The pathogenesis of IgA nephropathy. Curr Opin Nephrol Hypertens 20: 153–160, 2011 PubMed

Wyatt RJ, Julian BA: IgA nephropathy. N Engl J Med 368: 2402–2414, 2013 PubMed

Novak J, Julian BA, Mestecky J, Renfrow MB: Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol 34: 365–382, 2012 PubMed

Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J: Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 104: 73–81, 1999 PubMed PMC

Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J: Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119: 1668–1677, 2009 PubMed PMC

Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K, Gharavi AG, Novak J, Zhang H: The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 82: 790–796, 2012 PubMed PMC

Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J: Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23: 1579–1587, 2012 PubMed PMC

Mestecky J, Raska M, Julian BA, Gharavi AG, Renfrow MB, Moldoveanu Z, Novak L, Matousovic K, Novak J: IgA nephropathy: Molecular mechanisms of the disease. Annu Rev Pathol 8: 217–240, 2013 PubMed

Raposo B, Dobritzsch D, Ge C, Ekman D, Xu B, Lindh I, Förster M, Uysal H, Nandakumar KS, Schneider G, Holmdahl R: Epitope-specific antibody response is controlled by immunoglobulin V(H) polymorphisms. J Exp Med 211: 405–411, 2014 PubMed PMC

Novak J, Moldoveanu Z, Julian BA, Raska M, Wyatt RJ, Suzuki Y, Tomino Y, Gharavi AG, Mestecky J, Suzuki H: Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: Role of mucosal immune system. Adv Otorhinolaryngol 72: 60–63, 2011 PubMed

Prabakaran P, Zhu Z, Chen W, Gong R, Feng Y, Streaker E, Dimitrov DS: Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing. Front Microbiol 3: 277, 2012 PubMed PMC

Yuan T, Li J, Zhang MY: A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins. MAbs 3: 402–407, 2011 PubMed PMC

Vale AM, Kapoor P, Skibinski GA, Elgavish A, Mahmoud TI, Zemlin C, Zemlin M, Burrows PD, Nobrega A, Kearney JF, Briles DE, Schroeder HW Jr: The link between antibodies to OxLDL and natural protection against pneumococci depends on D(H) gene conservation. J Exp Med 210: 875–890, 2013 PubMed PMC

Kim N, Jinks-Robertson S: Transcription as a source of genome instability. Nat Rev Genet 13: 204–214, 2012 PubMed PMC

Laffleur B, Denis-Lagache N, Péron S, Sirac C, Moreau J, Cogné M: AID-induced remodeling of immunoglobulin genes and B cell fate. Oncotarget 5: 1118–1131, 2014 PubMed PMC

Storb U: Why does somatic hypermutation by AID require transcription of its target genes? Adv Immunol 122: 253–277, 2014 PubMed

Nagaoka H, Tran TH, Kobayashi M, Aida M, Honjo T: Preventing AID, a physiological mutator, from deleterious activation: regulation of the genomic instability that is associated with antibody diversity. Int Immunol 22: 227–235, 2010 PubMed

Liu M, Duke JL, Richter DJ, Vinuesa CG, Goodnow CC, Kleinstein SH, Schatz DG: Two levels of protection for the B cell genome during somatic hypermutation. Nature 451: 841–845, 2008 PubMed

Adhikary R, Yu W, Oda M, Zimmermann J, Romesberg FE: Protein dynamics and the diversity of an antibody response. J Biol Chem 287: 27139–27147, 2012 PubMed PMC

Raghunathan G, Smart J, Williams J, Almagro JC: Antigen-binding site anatomy and somatic mutations in antibodies that recognize different types of antigens. J Mol Recognit 25: 103–113, 2012 PubMed

Brooks CL, Schietinger A, Borisova SN, Kufer P, Okon M, Hirama T, Mackenzie CR, Wang LX, Schreiber H, Evans SV: Antibody recognition of a unique tumor-specific glycopeptide antigen. Proc Natl Acad Sci U S A 107: 10056–10061, 2010 PubMed PMC

Foreman AL, Van de Water J, Gougeon ML, Gershwin ME: B cells in autoimmune diseases: insights from analyses of immunoglobulin variable (Ig V) gene usage. Autoimmun Rev 6: 387–401, 2007 PubMed PMC

Kiryluk K, Novak J, Gharavi AG: Pathogenesis of immunoglobulin A nephropathy: Recent insight from genetic studies. Annu Rev Med 64: 339–356, 2013 PubMed PMC

Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata S, Prakash S, Shapiro S, Fischman C, Snyder HJ, Appel G, Izzi C,, Viola BF, Dallera N, Del. Vecchio L, Barlassina C, Salvi E, Amoroso A, Bertinetto F, Savoldi S, Rocchietti M, Amore A, Peruzzi L, Coppo R, Salvadori M, Ravani P, Magistroni R, Ghiggeri GM, Caridi G, Bodria M, Lugani F, Allegri L, Delsante M, Maiorana M, Magnano A, Frasca G, Boscutti G, Ponticelli C, Mignani R, Marcantoni C, Santoro D, Pani A, Feriozzi S, Galliani M, Gigante M, Gesualdo L, Zamboli P, Maixnerová D, Tesar V, Eitner F, Rauen T, Floege J, Nagy J, Mucha K, Pączek L, Zaniew M, Mizerska-Wasiak M, Roszkowska-Blaim M, Pawlaczyk K, Gale D, Thibaudin L, Berthoux F, Canaud G, Boland A, Metzger M, Panzer U, Suzuki H, Goto S, Narita I, Caliskan Y, Xie J, Hou P, Chen N, Zhang H, Wyatt RJ, Novak J, Julian BA, Feehally J, Stengel B, Cusi D, Lifton RP, Gharavi AG: Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46: 1187–1196, 2014 PubMed PMC

Placzek WJ, Makita Y, Renfrow MB, Julian BA, Suzuki Y, Novak J, Suzuki H: Serum levels of galactose-deficient IgA1 in patients with IgA nephropathy correlate with serum levels of IgG autoantibodies. J Am Soc Nephrol 26: 258A, 2015 PubMed

Kil LP, Hendriks RW: Aberrant B cell selection and activation in systemic lupus erythematosus. Int Rev Immunol 32: 445–470, 2013 PubMed

Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP: Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43: 321–327, 2011 PubMed PMC

Matsuda F, Ishii K, Bourvagnet P, Kuma K, Hayashida H, Miyata T, Honjo T: The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. J Exp Med 188: 2151–2162, 1998 PubMed PMC

Niemi MH, Takkinen K, Amundsen LK, Söderlund H, Rouvinen J, Höyhtyä M: The testosterone binding mechanism of an antibody derived from a naïve human scFv library. J Mol Recognit 24: 209–219, 2011 PubMed

IgA Nephropathy: Pleiotropic impact of Epstein-Barr virus infection on immunopathogenesis and racial incidence of the disease

Role of Epstein-Barr Virus in Pathogenesis and Racial Distribution of IgA Nephropathy

The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy